A decade of change

Nature Reviews Drug Discovery

Volumn 11, Issue 1, 2012, Pages 17-18

  Arrowsmith, John ^a  

^a THOMSON REUTERS   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ADALIMUMAB; AMLODIPINE BESYLATE; ATORVASTATIN; CELECOXIB; CLOPIDOGREL; ESOMEPRAZOLE; ETANERCEPT; FLUTICASONE PROPIONATE PLUS SALMETEROL; INFLIXIMAB; LANSOPRAZOLE; LORATADINE; OLANZAPINE; OMEPRAZOLE; PAROXETINE; QUETIAPINE; RECOMBINANT ERYTHROPOIETIN; ROSUVASTATIN; SIMVASTATIN;

BUDGET; CAPITAL; DRUG INDUSTRY; DRUG MARKETING; DRUG RESEARCH; PRIORITY JOURNAL; PRODUCT DEVELOPMENT; SHORT SURVEY;

DRUG INDUSTRY; HUMANS; PHARMACEUTICAL PREPARATIONS; PRODUCT SURVEILLANCE, POSTMARKETING; RESEARCH;

EID: 84855383596     PISSN: 14741776     EISSN: 14741784     Source Type: Journal    
DOI: 10.1038/nrd3630     Document Type: Short Survey

References (3)

1. Lamattina, J. The impact of mergers on pharmaceutical R&D. Nature Rev. Drug Discov.10, 559 (2011).
2. Slatko, J. The future belongs to biologics. Med Ad News 16, 34 (2010).
3. Arrowsmith, J. Trial watch: Phase II failures: 2008-2010. Nature Rev. Drug Discov. 10, 328-329 (2011).